Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina

Semiz, Sabina; Dujić, Tanja; Ostanek, Barbara; Prnjavorac, Besim; Bego, Tamer; Malenica, Maja; Mlinar, Barbara; Marc, Janja; Čaušević, Adlija
February 2011
Medicinski Glasnik;Feb2011, Vol. 8 Issue 1, p84
Academic Journal
No abstract available.


Related Articles

  • Farmacogenética y farmacogenómica: hacia una medicina personalizada. Gurrola, Samuel Banda; Torres Guevara, Esteban Jovani; Chávez Ramírez, Héctor Javier // Revista de la Facultad de Medicina de la UNAM;mar/abr2010, Vol. 53 Issue 2, p55 

    Alter the whole genome sequentiation, there is a bigger gap between the capabilities of biomedical technology and the diagnostic of the clinician on its practice. One of the genomic sciences is the pharmacogenomics; the discipline, like its predecessor, pharmacogenetics, attemps to predict the...

  • Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics. Siew Hua Gan; Ismail, Rusli; Wan Adnan, Wan Aasim; Zulmi, Wan // Molecular Diagnosis & Therapy;May2007, Vol. 11 Issue 3, p171 

    Background and objective: Tramadol is metabolized by the highly polymorphic enzyme cytochrome P450 (CYP)2D6. Patients with different CYP2D6 genotypes may respond differently to tramadol in terms of pain relief and adverse events. In this study, we compare the pharmacokinetics and effects of...

  • ASSOCIATION OF POLYMORPHISM OF CYP2D6 AND CYP2C9 GENES ENCODING P-450 PROTEINS OF CYTOCHROME WITH ARTERIAL HYPERTENSION. Borodulin, V. B.; Shevchenko, O. V.; Bychkov, E. N.; Kiselev, A. R.; Reshetko, O. V.; Posnenkova, O. M.; Saratsev, A. V.; Losev, O. E. // Saratov Journal of Medical Scientific Research / Saratovskii Nau;Oct-Dec2012, Vol. 8 Issue 4, p933 

    Gene polymorphisms of cytochrome P-450 CYP2 encoding proteins of cytochrome P-450 are essential for antihypertensive drugs metabolism. Purpose: We study the associations of functionally defective allele variants of CYP2D6 gene and CYP2C9 gene with the degree of arterial hypertension (AH)....

  • Medicina personalizada: farmacogenómica y farmacoepigenética. Bravo, Susana B.; Caminos, Jorge E.; Schmalbach, Javier Hernando Eslava // Colombian Journal of Anesthesiology / Revista Colombiana de Anes;Jul2011, Vol. 39 Issue 3, p308 

    No abstract available.

  • Pharmacogenetics of Phase I and Phase II Drug Metabolism. Crettol, Severine; Petrovic, Nenad; Murray, Michael // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p204 

    Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug...

  • Polymorphisms of Human N-Acetyltransferases and Cancer Risk. Agüdez, José A. G. // Current Drug Metabolism;Jul2008, Vol. 9 Issue 6, p520 

    Human arylamine N-acetyltransferases (CoASAc; NAT, EC NAT1 and NAT2 play a key role in the metabolism of drugs and environmental chemicals and in the metabolic activation and detoxification of procarcinogens. Phenotyping analyses have revealed an association between NAT enzyme...

  • China,P.R.∣ Mainland: Forecast Brief - 2011 Edition. Kelly, Robert C. // CountryWatch Forecast Brief - China;2011, preceding p1 

    The 2011 edition of "CountryWatch Forecasts: China: Forecast Brief" is presented. It offers a comprehensive view on the global economy with updates on the economic trends in the U.S., Europe and Asia. Charts depicting the year-on-year real gross domestic product (GDP) rates, foreign exchange...

  • Determinants of Steady-State Torasemide Pharmacokinetics: Impact of Pharmacogenetic Factors, Gender and Angiotensin II Receptor Blockers. Werner, Dierk; Werner, Ulrike; Meybaum, Annett; Schmidt, Boris; Umbreen, Sumaira; Grosch, Anton; Lestin, Heiko G.; Graf, Bernhard; Zolk, Oliver; Fromm, Martin F. // Clinical Pharmacokinetics;2008, Vol. 47 Issue 5, p323 

    BACKGROUND: Torasemide is frequently used for the treatment of hypertension and heart failure. However, the determinants of torasemide pharmacokinetics in patients during steady-state conditions are largely unknown. We therefore explored the impact of genetic polymorphisms of cytochrome P450...

  • The Star-Allele Nomenclature: Retooling for Translational Genomics. Robarge, J. D.; Li, L.; Desta, Z.; Nguyen, A.; Flockhart, D. A. // Clinical Pharmacology & Therapeutics;Sep2007, Vol. 82 Issue 3, p244 

    The star-allele nomenclature is the result of efforts to standardize genetic polymorphism annotation for the cytochrome P450 genes. As clinical pharmacogenetic testing becomes widespread, it is important that this system effectively communicate a patient's genotype and predicted clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics